Compare HMY & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMY | EXAS |
|---|---|---|
| Founded | 1950 | 1995 |
| Country | South Africa | United States |
| Employees | 34350 | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 19.7B |
| IPO Year | N/A | 2000 |
| Metric | HMY | EXAS |
|---|---|---|
| Price | $19.09 | $103.47 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 17 |
| Target Price | $16.00 | ★ $86.62 |
| AVG Volume (30 Days) | ★ 3.9M | 1.9M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | N/A | ★ 80.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,144,000.00 |
| Revenue This Year | $40.34 | $15.37 |
| Revenue Next Year | $22.08 | $12.41 |
| P/E Ratio | $15.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.67 | $38.88 |
| 52 Week High | $26.04 | $103.87 |
| Indicator | HMY | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 38.99 | 58.57 |
| Support Level | $13.85 | $102.95 |
| Resistance Level | $19.59 | $103.77 |
| Average True Range (ATR) | 0.85 | 0.31 |
| MACD | -0.27 | -0.07 |
| Stochastic Oscillator | 18.18 | 48.13 |
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.